Credit Suisse’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $8.78M | Sell |
25,397
-6,670
| -21% | -$2.19M | 0.01% | 976 |
|
|
2023
Q4 | $10.4M | Buy |
32,067
+2,814
| +10% | +$882K | 0.01% | 909 |
|
|
2023
Q3 | $10.5M | Sell |
29,253
-6,229
| -18% | -$2.4M | 0.01% | 883 |
|
|
2023
Q2 | $13.5M | Sell |
35,482
-7,993
| -18% | -$3.25M | 0.01% | 799 |
|
|
2023
Q1 | $20.8M | Buy |
43,475
+9,914
| +30% | +$4.64M | 0.02% | 657 |
|
|
2022
Q4 | $14.1M | Sell |
33,561
-2,217
| -6% | -$895K | 0.02% | 784 |
|
|
2022
Q3 | $14.9M | Buy |
35,778
+1,031
| +3% | +$514K | 0.02% | 754 |
|
|
2022
Q2 | $17.2M | Sell |
34,747
-4,407
| -11% | -$2.3M | 0.02% | 739 |
|
|
2022
Q1 | $22.1M | Sell |
39,154
-159
| -0.4% | -$95.8K | 0.02% | 732 |
|
|
2021
Q4 | $29.7M | Sell |
39,313
-73,621
| -65% | -$55.1M | 0.02% | 887 |
|
|
2021
Q3 | $84.2M | Sell |
112,934
-24,554
| -18% | -$18.4M | 0.05% | 429 |
|
|
2021
Q2 | $88.8M | Buy |
137,488
+56,990
| +71% | +$34.7M | 0.05% | 425 |
|
|
2021
Q1 | $46M | Buy |
80,498
+25,031
| +45% | +$14.8M | 0.02% | 746 |
|
|
2020
Q4 | $32.3M | Buy |
55,467
+8,610
| +18% | +$4.9M | 0.02% | 915 |
|
|
2020
Q3 | $24.2M | Buy |
46,857
+1,552
| +3% | +$786K | 0.01% | 937 |
|
|
2020
Q2 | $20.5M | Buy |
45,305
+8,900
| +24% | +$3.93M | 0.01% | 935 |
|
|
2020
Q1 | $12.8M | Buy |
36,405
+6,616
| +22% | +$2.43M | 0.01% | 1061 |
|
|
2019
Q4 | $11M | Sell |
29,789
-276
| -0.9% | -$97.3K | 0.01% | 1355 |
|
|
2019
Q3 | $10M | Buy |
30,065
+8,965
| +42% | +$2.92M | 0.01% | 1307 |
|
|
2019
Q2 | $6.59M | Buy |
21,100
+1,309
| +7% | +$392K | 0.01% | 1565 |
|
|
2019
Q1 | $6.05M | Sell |
19,791
-821
| -4% | -$222K | 0.01% | 1573 |
|
|
2018
Q4 | $4.79M | Sell |
20,612
-3,955
| -16% | -$1.06M | 0.01% | 1612 |
|
|
2018
Q3 | $7.69M | Buy |
24,567
+934
| +4% | +$290K | 0.01% | 1419 |
|
|
2018
Q2 | $6.82M | Sell |
23,633
-2,346
| -9% | -$648K | 0.01% | 1510 |
|
|
2018
Q1 | $6.5M | Buy |
25,979
+964
| +4% | +$245K | 0.01% | 1535 |
|
|
2017
Q4 | $5.97M | Sell |
25,015
-24,720
| -50% | -$5.99M | 0.01% | 1640 |
|
|
2017
Q3 | $11.1M | Buy |
49,735
+14,796
| +42% | +$3.33M | 0.01% | 1192 |
|
|
2017
Q2 | $7.91M | Buy |
34,939
+14,335
| +70% | +$3.12M | 0.01% | 1340 |
|
|
2017
Q1 | $4.11M | Buy |
20,604
+4,177
| +25% | +$805K | ﹤0.01% | 1800 |
|
|
2016
Q4 | $2.99M | Sell |
16,427
-303,995
| -95% | -$51.8M | ﹤0.01% | 2100 |
|
|
2016
Q3 | $52.5M | Buy |
320,422
+87,664
| +38% | +$13.3M | 0.05% | 402 |
|
|
2016
Q2 | $33.3M | Buy |
232,758
+144,933
| +165% | +$20.7M | 0.04% | 542 |
|
|
2016
Q1 | $12M | Sell |
87,825
-135,494
| -61% | -$17.8M | 0.01% | 1007 |
|
|
2015
Q4 | $31M | Buy |
223,319
+128,704
| +136% | +$17.8M | 0.04% | 568 |
|
|
2015
Q3 | $12.7M | Buy |
94,615
+34,908
| +58% | +$5.02M | 0.02% | 982 |
|
|
2015
Q2 | $8.99M | Sell |
59,707
-210,004
| -78% | -$30M | 0.01% | 1322 |
|
|
2015
Q1 | $36.5M | Buy |
269,711
+249,687
| +1,247% | +$30.9M | 0.04% | 545 |
|
|
2014
Q4 | $2.41M | Sell |
20,024
-2,781
| -12% | -$320K | ﹤0.01% | 2388 |
|
|
2014
Q3 | $2.59M | Sell |
22,805
-8,185
| -26% | -$970K | ﹤0.01% | 2279 |
|
|
2014
Q2 | $3.71M | Buy |
30,990
+9,089
| +42% | +$1.11M | ﹤0.01% | 2217 |
|
|
2014
Q1 | $2.81M | Sell |
21,901
-3,053
| -12% | -$391K | ﹤0.01% | 2249 |
|
|
2013
Q4 | $3.08M | Sell |
24,954
-6,229
| -20% | -$759K | ﹤0.01% | 2269 |
|
|
2013
Q3 | $3.67M | Buy |
31,183
+96
| +0.3% | +$11.3K | ﹤0.01% | 1897 |
|
|
2013
Q2 | $3.49M | Buy |
+31,087
| New | +$3.65M | ﹤0.01% | 1861 |
|
Other funds holding BIO
VAM
Credit Suisse's BIO Position: Q1 2024 in Review
Credit Suisse reduced its Bio-Rad Laboratories Class A (BIO) stake by 21% in Q1 2024, selling an estimated $2.19M and leaving 25,397 shares worth $8.78M. The position accounts for 0.01% of the portfolio, ranked #976.
Credit Suisse first reported a position in BIO in Q2 2013 and has held it in 44 quarters since. The position peaked at $88.8M in Q2 2021. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.
- Credit Suisse held 25,397 shares of Bio-Rad Laboratories Class A worth $8.78M as of Q1 2024.
- Credit Suisse sold 6,670 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $2.19M.
- Bio-Rad Laboratories Class A made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #976 holding.
- Credit Suisse first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Bio-Rad Laboratories Class A position peaked at $88.8M in Q2 2021.
- 466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.